|
WO2003085110A2
(en)
|
2002-04-05 |
2003-10-16 |
Santaris Pharma A/S |
Oligomeric compounds for the modulation hif-1alpha expression
|
|
US7713738B2
(en)
|
2003-02-10 |
2010-05-11 |
Enzon Pharmaceuticals, Inc. |
Oligomeric compounds for the modulation of survivin expression
|
|
PT1592793E
(pt)
|
2003-02-10 |
2009-09-30 |
Santaris Pharma As |
Compostos oligoméricos para a modulação da expressão de survivina
|
|
CA2519860C
(en)
|
2003-03-21 |
2018-01-16 |
Santaris Pharma A/S |
Short interfering rna (sirna) analogues
|
|
RU2377301C2
(ru)
|
2003-12-23 |
2009-12-27 |
Сантарис Фарма А/С |
ОЛИГОМЕРНОЕ СОЕДИНЕНИЕ, ПОНИЖАЮЩЕЕ ЭКСПРЕССИЮ ЧЕЛОВЕЧЕСКОГО ГЕНА Bcl-2, КОНЪЮГАТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ ОЛИГОМЕРНОГО СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ РАКА
|
|
US9447138B2
(en)
|
2004-11-09 |
2016-09-20 |
Roche Innovation Center Copenhagen A/S |
Potent LNA oligonucleotides for the inhibition of HIF-1a expression
|
|
KR20070095882A
(ko)
|
2004-11-09 |
2007-10-01 |
산타리스 팔마 에이/에스 |
Ｌｎａ 올리고뉴클레오티드 및 암의 치료
|
|
AU2005304112B2
(en)
|
2004-11-09 |
2009-06-04 |
Roche Innovation Center Copenhagen A/S |
Potent LNA oligonucleotides for the inhibition of HIF-1a expression
|
|
EP1971371B1
(en)
|
2005-12-01 |
2015-08-05 |
Pronai Therapeutics, Inc. |
Cancer therapies and pharmaceutical compositions used therein
|
|
WO2007107162A2
(en)
|
2006-03-23 |
2007-09-27 |
Santaris Pharma A/S |
Small internally segmented interfering rna
|
|
EP2666859B1
(en)
|
2006-04-03 |
2019-01-02 |
Roche Innovation Center Copenhagen A/S |
Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
|
|
CA2648132C
(en)
|
2006-04-03 |
2019-05-28 |
Santaris Pharma A/S |
Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
|
|
CA2681406A1
(en)
|
2007-03-22 |
2008-09-25 |
Santaris Pharma A/S |
Rna antagonist compounds for the inhibition of apo-b100 expression
|
|
WO2008113832A2
(en)
|
2007-03-22 |
2008-09-25 |
Santaris Pharma A/S |
SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
|
|
ES2798758T3
(es)
|
2007-06-06 |
2020-12-14 |
Sarepta Therapeutics Inc |
Proteínas variantes de empalme her2 y her3 solubles, oligonucleótidos de cambio de empalme y su uso en el tratamiento de enfermedades
|
|
WO2009027978A1
(en)
|
2007-08-30 |
2009-03-05 |
Hadasit Medical Research Services & Development Ltd. |
NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS
|
|
EP2623599B1
(en)
|
2007-10-04 |
2019-01-02 |
Roche Innovation Center Copenhagen A/S |
Micromirs
|
|
EP2212437A4
(en)
|
2007-11-07 |
2011-09-28 |
Univ British Columbia |
MICROFLUIDIC DEVICE AND METHOD OF USING THE DEVICE
|
|
EP2268811A1
(en)
|
2008-03-07 |
2011-01-05 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of microrna related diseases
|
|
ES2541442T3
(es)
|
2008-08-01 |
2015-07-20 |
Roche Innovation Center Copenhagen A/S |
Modulación mediada por microARN de factores estimulantes de colonias
|
|
ES2599979T3
(es)
|
2009-04-24 |
2017-02-06 |
Roche Innovation Center Copenhagen A/S |
Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
|
|
US8563528B2
(en)
|
2009-07-21 |
2013-10-22 |
Santaris Pharma A/S |
Antisense oligomers targeting PCSK9
|
|
WO2011105900A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
|
|
WO2011105901A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 9 (c9) and uses thereof
|
|
WO2011105902A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-beta (c8-beta) and uses thereof
|
|
GB201012418D0
(en)
|
2010-07-23 |
2010-09-08 |
Santaris Pharma As |
Process
|
|
WO2012027206A1
(en)
|
2010-08-24 |
2012-03-01 |
Merck Sharp & Dohme Corp. |
SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
|
|
BR112015010220A2
(pt)
|
2012-11-05 |
2017-12-05 |
Pronai Therapeutics Inc |
métodos de utilização de biomarcadores para tratamento de câncer
|
|
WO2014108759A1
(en)
|
2013-01-14 |
2014-07-17 |
Pierfrancesco Tassone |
INHIBITORS OF miRNAs 221 AND 222 FOR ANTI-TUMOR ACTIVITY IN MULTIPLE MYELOMA
|
|
ES2770667T3
(es)
|
2013-06-27 |
2020-07-02 |
Roche Innovation Ct Copenhagen As |
Oligómeros antisentido y conjugados que se dirigen a PCSK9
|
|
WO2015075166A1
(en)
|
2013-11-22 |
2015-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of a bacterial infection
|
|
US9765332B2
(en)
|
2014-01-29 |
2017-09-19 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Oligonucleotides and methods for inhibiting or reducing bacterial biofilms
|
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
|
WO2016041058A1
(en)
|
2014-09-18 |
2016-03-24 |
The University Of British Columbia |
Allele-specific therapy for huntington disease haplotypes
|
|
CN107109411B
(zh)
|
2014-10-03 |
2022-07-01 |
冷泉港实验室 |
核基因输出的定向增加
|
|
JP6835826B2
(ja)
*
|
2015-08-24 |
2021-02-24 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Ｌｎａ−ｇプロセス
|
|
EP3359685B1
(en)
|
2015-10-09 |
2026-01-28 |
University Of Southampton |
Modulation of gene expression for deregulated protein expression
|
|
EP3933041B1
(en)
|
2015-12-14 |
2024-01-31 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of autosomal dominant retardation
|
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
|
WO2018024849A1
(en)
|
2016-08-03 |
2018-02-08 |
Aalborg Universitet |
ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
|
|
SG11202001590RA
(en)
|
2017-08-25 |
2020-03-30 |
Stoke Therapeutics Inc |
Antisense oligomers for treatment of conditions and diseases
|
|
WO2019076919A1
(en)
|
2017-10-17 |
2019-04-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
COMBINED TREATMENT OF CYSTIC FIBROSIS
|
|
US12060558B2
(en)
|
2018-05-04 |
2024-08-13 |
Stoke Therapeutics, Inc. |
Methods and compositions for treatment of cholesteryl ester storage disease
|
|
KR20210134003A
(ko)
|
2019-02-27 |
2021-11-08 |
스톡 테라퓨틱스, 인크. |
병태 및 질환의 치료를 위한 안티센스 올리고머
|
|
US20220251567A1
(en)
|
2019-07-10 |
2022-08-11 |
Inserm (Institut National De La Santè Et De La Recherche Médicale) |
Methods for the treatment of epilepsy
|
|
IT201900017234A1
(it)
|
2019-09-25 |
2021-03-25 |
Int Centre For Genetic Engineering And Biotechnology |
Anti-miRNA per il trattamento del leiomioma
|
|
WO2021074657A1
(en)
|
2019-10-17 |
2021-04-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination treatment for cystic fibrosis
|
|
IL292286A
(en)
*
|
2019-10-18 |
2022-06-01 |
Daiichi Sankyo Co Ltd |
Production method for bicyclic phosphoramidite
|
|
CA3161586A1
(en)
*
|
2019-11-13 |
2021-05-20 |
Nippon Shinyaku Co., Ltd. |
Method for producing oligonucleic acid compound
|
|
US20230016983A1
(en)
|
2019-11-19 |
2023-01-19 |
lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) |
Antisense oligonucleotides and thier use for the treatment of cancer
|
|
BR112022022889A2
(pt)
|
2020-05-11 |
2023-04-04 |
Stoke Therapeutics Inc |
Oligômeros antissentido de opa1 para tratamento de condições e doenças
|
|
KR20230050336A
(ko)
|
2020-07-10 |
2023-04-14 |
인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) |
뇌전증을 치료하기 위한 방법과 조성물
|
|
WO2022124410A1
(ja)
*
|
2020-12-11 |
2022-06-16 |
ヤマサ醤油株式会社 |
シトシン型架橋型ヌクレオシドアミダイト結晶及びその製造方法
|
|
IL304956A
(en)
|
2021-02-12 |
2023-10-01 |
Merand Pharmaceuticals Inc |
Agents, compositions, and methods for the treatment of hypoxia and ischemia-related disorders
|
|
US20240182889A1
(en)
|
2021-03-26 |
2024-06-06 |
Neumirna Therapeutics Aps |
Microrna-27b inhibitors
|
|
EP4313073A1
(en)
|
2021-03-26 |
2024-02-07 |
Neumirna Therapeutics ApS |
Microrna-134 inhibitors
|
|
JP2024522272A
(ja)
|
2021-06-04 |
2024-06-13 |
ニューミルナ セラピューティクス エーピーエス |
アデノシンキナーゼを標的とするアンチセンスオリゴヌクレオチド
|
|
EP4389892A4
(en)
|
2021-08-17 |
2025-12-10 |
Korea Advanced Inst Sci & Tech |
Antisense oligonucleotide targeting the CAV3.1 gene and its uses
|
|
CA3228833A1
(en)
|
2021-08-19 |
2023-02-23 |
Neumirna Therapeutics Aps |
Antisense oligonucleotides targeting adenosine kinase
|
|
JP7772362B2
(ja)
*
|
2021-12-21 |
2025-11-18 |
シンクレスト株式会社 |
人工核酸モノマーの製造方法
|
|
WO2023152369A1
(en)
|
2022-02-14 |
2023-08-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis
|
|
EP4558149A1
(en)
|
2022-07-21 |
2025-05-28 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
|
EP4332239A1
(en)
|
2022-08-30 |
2024-03-06 |
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. |
Mir-based assay for gastro-entero-pancreatic neuroendocrine tumor diagnosis and prognosis
|
|
EP4646478A1
(en)
|
2023-01-06 |
2025-11-12 |
Institut National de la Santé et de la Recherche Médicale |
Intravenous administration of antisense oligonucleotides for the treatment of pain
|
|
EP4450626A1
(en)
|
2023-04-21 |
2024-10-23 |
IFOM - Istituto Fondazione di Oncologia Molecolare ETS |
Fnip2 inhibitors for treating ataxia telangiectasia
|
|
WO2025008406A1
(en)
|
2023-07-04 |
2025-01-09 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of cancer
|
|
EP4512899A1
(en)
|
2023-08-23 |
2025-02-26 |
Lipigon Pharmaceuticals AB |
Angptl4 aso compositions for treatment of atherosclerosis in humans
|
|
CN117233282B
(zh)
*
|
2023-09-14 |
2024-12-20 |
上海奥锐特生物科技有限公司 |
2-氰乙基-n,n,n’,n’-四异丙基亚磷酰二胺的检测方法
|
|
WO2025237990A1
(en)
|
2024-05-14 |
2025-11-20 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
|
|
WO2026061986A1
(en)
|
2024-09-17 |
2026-03-26 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotide (aso)-mediated down-regulation of cd33 to safely enrich for genetically modified cells
|
|
WO2026068729A1
(en)
|
2024-09-26 |
2026-04-02 |
Neumirna Therapeutics Aps |
Antimir-27b for treatment of parkinson's disease
|